Citadel Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.28M | Sell |
65,540
-163,184
| -71% | -$3.99M | ﹤0.01% | 7109 |
|
|
2025
Q4 | $6.13M | Buy |
228,724
+1,949
| +0.9% | +$50.2K | ﹤0.01% | 3967 |
|
|
2025
Q3 | $6.04M | Sell |
226,775
-65,570
| -22% | -$1.69M | ﹤0.01% | 4014 |
|
|
2025
Q2 | $6.71M | Buy |
292,345
+136,366
| +87% | +$3.38M | ﹤0.01% | 3620 |
|
|
2025
Q1 | $4.52M | Buy |
155,979
+15,566
| +11% | +$497K | ﹤0.01% | 4041 |
|
|
2024
Q4 | $5.21M | Buy |
140,413
+5,176
| +4% | +$237K | ﹤0.01% | 3897 |
|
|
2024
Q3 | $6.56M | Sell |
135,237
-127,914
| -49% | -$5.61M | ﹤0.01% | 3514 |
|
|
2024
Q2 | $10.5M | Buy |
263,151
+195,454
| +289% | +$8.1M | ﹤0.01% | 2708 |
|
|
2024
Q1 | $2.97M | Sell |
67,697
-48,502
| -42% | -$2.5M | ﹤0.01% | 4808 |
|
|
2023
Q4 | $7.19M | Sell |
116,199
-12,516
| -10% | -$657K | ﹤0.01% | 3286 |
|
|
2023
Q3 | $5.92M | Sell |
128,715
-49,235
| -28% | -$2.69M | ﹤0.01% | 3387 |
|
|
2023
Q2 | $10.2M | Buy |
177,950
+146,609
| +468% | +$6.5M | ﹤0.01% | 2644 |
|
|
2023
Q1 | $1.18M | Sell |
31,341
-11,166
| -26% | -$366K | ﹤0.01% | 6426 |
|
|
2022
Q4 | $1.19M | Sell |
42,507
-132,758
| -76% | -$3.85M | ﹤0.01% | 6477 |
|
|
2022
Q3 | $4.92M | Buy |
175,265
+133,867
| +323% | +$4.37M | ﹤0.01% | 3902 |
|
|
2022
Q2 | $1.44M | Sell |
41,398
-196,485
| -83% | -$7.01M | ﹤0.01% | 6214 |
|
|
2022
Q1 | $8.54M | Buy |
237,883
+24,361
| +11% | +$691K | ﹤0.01% | 3223 |
|
|
2021
Q4 | $4.97M | Buy |
+213,522
| New | +$4.37M | ﹤0.01% | 4304 |
|
|
2021
Q3 | – | Sell |
-24,373
| Closed | -$492K | – | 13743 |
|
|
2021
Q2 | $492K | Sell |
24,373
-15,056
| -38% | -$284K | ﹤0.01% | 10098 |
|
|
2021
Q1 | $722K | Sell |
39,429
-30,709
| -44% | -$571K | ﹤0.01% | 8874 |
|
|
2020
Q4 | $1.41M | Buy |
70,138
+16,164
| +30% | +$315K | ﹤0.01% | 6070 |
|
|
2020
Q3 | $1.01M | Buy |
53,974
+16,234
| +43% | +$327K | ﹤0.01% | 6007 |
|
|
2020
Q2 | $848K | Sell |
37,740
-48,475
| -56% | -$888K | ﹤0.01% | 6132 |
|
|
2020
Q1 | $1.28M | Buy |
+86,215
| New | +$1.5M | ﹤0.01% | 4899 |
|
|
2019
Q4 | – | Sell |
-132,053
| Closed | -$2.62M | – | 9057 |
|
|
2019
Q3 | $2.62M | Buy |
132,053
+74,767
| +131% | +$1.56M | ﹤0.01% | 4057 |
|
|
2019
Q2 | $1.21M | Buy |
57,286
+43,126
| +305% | +$902K | ﹤0.01% | 5386 |
|
|
2019
Q1 | $289K | Sell |
14,160
-17,854
| -56% | -$400K | ﹤0.01% | 7665 |
|
|
2018
Q4 | $637K | Buy |
+32,014
| New | +$631K | ﹤0.01% | 6023 |
|
|
2018
Q2 | – | Sell |
-34,180
| Closed | -$641K | – | 8767 |
|
|
2018
Q1 | $641K | Buy |
+34,180
| New | +$643K | ﹤0.01% | 5473 |
|
|
2017
Q3 | – | Sell |
-92,576
| Closed | -$1.65M | – | 7485 |
|
|
2017
Q2 | $1.65M | Sell |
92,576
-262,990
| -74% | -$4.17M | ﹤0.01% | 3416 |
|
|
2017
Q1 | $5.16M | Buy |
355,566
+337,079
| +1,823% | +$5.3M | ﹤0.01% | 2014 |
|
|
2016
Q4 | $341K | Sell |
18,487
-47,633
| -72% | -$927K | ﹤0.01% | 5500 |
|
|
2016
Q3 | $1.25M | Sell |
66,120
-149,111
| -69% | -$2.71M | ﹤0.01% | 3528 |
|
|
2016
Q2 | $3.47M | Buy |
215,231
+202,862
| +1,640% | +$2.86M | ﹤0.01% | 2160 |
|
|
2016
Q1 | $148K | Buy |
12,369
+2,033
| +20% | +$24K | ﹤0.01% | 5835 |
|
|
2015
Q4 | $147K | Buy |
+10,336
| New | +$137K | ﹤0.01% | 6230 |
|
|
2015
Q3 | – | Sell |
-73,670
| Closed | -$1.29M | – | 8847 |
|
|
2015
Q2 | $1.29M | Buy |
73,670
+15,508
| +27% | +$242K | ﹤0.01% | 3638 |
|
|
2015
Q1 | $870K | Buy |
58,162
+7,778
| +15% | +$104K | ﹤0.01% | 4111 |
|
|
2014
Q4 | $585K | Buy |
50,384
+34,684
| +221% | +$378K | ﹤0.01% | 4495 |
|
|
2014
Q3 | $183K | Buy |
+15,700
| New | +$164K | ﹤0.01% | 5810 |
|
Other funds holding AMPH
VCM
BTW
Citadel Advisors's AMPH Position: Q1 2026 in Review
Citadel Advisors reduced its Amphastar Pharmaceuticals (AMPH) stake by 71% in Q1 2026, selling an estimated $3.99M and leaving 65,540 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #7109.
Citadel Advisors first reported a position in AMPH in Q3 2014 and has held it in 40 quarters since. The position peaked at $10.5M in Q2 2024. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.
- Citadel Advisors held 65,540 shares of Amphastar Pharmaceuticals worth $1.28M as of Q1 2026.
- Citadel Advisors sold 163,184 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $3.99M.
- Amphastar Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7109 holding.
- Citadel Advisors first reported a position in Amphastar Pharmaceuticals in Q3 2014 and has held it in 40 quarters since.
- Citadel Advisors's Amphastar Pharmaceuticals position peaked at $10.5M in Q2 2024.
- 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.